Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.

Minaguchi H, H. Minaguchi, Uemura T, Tomohiro Uemura, T Uemura, Kazuhiro Shirasu, K Shirasu, Shirasu K
Progress in clinical and biological research · 1986 · vol. 225 , pp. 211–25 · PMID:3097667 · W2413959891
article OA: closed CC0 ⤵ 14 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This multicenter trial in Japan investigated the optimal dose of the LHRH agonist buserelin for treating endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Adult Antigens, Neoplasm Antigens, Neoplasm Antigens, Tumor-Associated, Carbohydrate Buserelin Buserelin Buserelin Clinical Trials as Topic Dose-Response Relationship, Drug Endometriosis Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (13)

Source provenance

europepmc
last seen: 2026-09-05T06:14:40.014199+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:40.384591+00:00
License: CC0 · commercial use OK